Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla – Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. EJSO 2017; 43: 672-679.
Published: 5th January 2018
Authors: Sávolt A, Péley G, Polgár C, Udvarhelyi N, Rubovszky G, Kovács E et al.
Median follow-up was 97 months in this study that included 474 women. Axillary recurrence occurred in 2 per cent after axillary dissection and 1.7 per cent after axillary radiotherapy (P=1.00). Disease-free survival (72.1 vs 77.4 per cent, respectively) and overall survival rates (77.9 vs 84.8 per cent) were also similar.Pubmed Link
You may also be interested in
Prospective randomized trial of use of in-house prepared low-cost radiopharmaceutical versus commercial radiopharmaceutical for sentinel lymph node biopsy in patients with early stage invasive breast cancer. World J Surg 2018; 42: 1391-1395.
Authors: Agarwal G, Rajan S, Mayilvaganan S, Mishra A, Krishnani N, Gambhir S et al.
Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis. The ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 2017; 318: 918-926.
Authors: Giuliano AG, Ballman KV, McCall L, Beitsch P, Brennan MB, Keleman PR et al.